home > news > detailed info

ERT Expands eCOA Solution for Higher Fidelity CNS Assessments


Partnership with Cogstate delivers digital cognitive assessments to improve the speed and effectiveness of clinical trials

PHILADELPHIA – July 22, 2020 – ERT, the global leader in clinical endpoint data collection, today announced a preferred partnership with the leading neuroscience technology company, Cogstate, Ltd. The collaboration enables ERT to expand its industry-leading electronic Clinical Outcome Assessment (eCOA) solution with digital cognitive endpoint measurement to improve safety and efficacy assessment in clinical trials, including capabilities for at-home testing.

Cognition is a combination of brain processes that are critical for almost every aspect of life, such as learning, attention, memory, language, reasoning, and decision making. Conventional assessments of cognitive endpoints have historically been vulnerable to complexities, variability, and error. Plagued with issues ranging from non-standardized administration and rater bias to manual scoring, these assessments are less likely to yield reliable and conclusive results. By delivering Cogstate’s proven digital brain health assessments on ERT’s eCOA platform, trial sponsors can overcome these issues and capture higher quality data to support the development of treatments for CNS and other disorders.

“Pharmaceutical researchers and regulators are increasingly focused on understanding the impact new treatments have on the brain, so now more than ever there is a need to use digital technologies to make cognitive assessments more rapid, reliable, accessible and actionable,” said Jim Mahon, Vice President and Chief Strategy and Marketing Officer at ERT. “By leveraging Cogstate’s digital CNS assessment through ERT’s eCOA platform, sponsors can dramatically streamline the measurement of CNS clinical outcomes, increase the quality of data, reduce patient and site burden by eliminating the need for duplicate hardware, log-ins and support desks, and gain the flexibility of remote administration for virtual visits.”

The Cogstate system includes highly automated neurocognitive tests with integrated analytics for understanding drug-effects related to areas of brain function such as attention, processing speed, motor function, executive function, and multiple aspects of memory. Cogstate’s digital assessments are delivered in the same eCOA application and visit workflow as ERT’s patient reported, clinician reported, or observer reported outcome assessments, overcoming the limitations of manual cognitive assessments and providing speed, efficiency, and data quality benefits for clinical trial sponsors.

“ERT is renowned for delivering the reliable patient assessment data clinical trial sponsors need to confidently evaluate the safety and efficacy of new drug candidates,” said Brad O’Connor, CEO of Cogstate. “We’re pleased to collaborate with them as they expand their CNS measurement capabilities and leverage digital technologies to deliver more precise cognitive assessments, ultimately helping researchers bring new treatments to patients in need.”

Click here for more information and to register for the upcoming webinar, “A Better Way to Measure Cognitive Safety and Tolerability.”
phone +1 800 961 5004
email 1818 Market Street, Suite 1000, Philadelphia, PA 19103
Print this page
Send to a friend
News and Press Releases

Northway Biotechpharma and Hansa Biopharma initiate a new Contract Development and Manufacturing project in immunological diseases

Vilnius, Lithuania, and Lund, Sweden - December 20th, 2019 – Northway Biotechpharma, a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO), and Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, today announced a new service agreement to develop the next generation of IgG cleaving enzymes.
More info >>

White Papers

Modifying MDI Canister Surfaces to Improve Drug Stability & Drug Delivery

Presspart Manufacturing Ltd

Hydrofluoroalkane (HFA)-based propellants are widely used in modern metered-dose inhalers (MDIs), due to their lack hazardous and environmentally-damaging effects. However, an HFA's active pharmaceutical ingredient can interact with the canister substrate, causing deposition of the drug to the canister walls, or interact with the solution, causing degradation and resulting in increased impurity levels. Over the past few years, a number of surface coatings have been developed that can be applied to MDI canisters and valve components, to protect the contents from deposition and degradation. More recently, plasma processes have been developed to modify and improve the surface energy performance of a MDI canister. This approach has a number of advantages to alternative coatings but requires careful optimisation to ensure the highest quality finish and MDI performance. Richard Turner, Business Development Director, Presspart Manufacturing Ltd, explains.
More info >>

Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement